Document Detail

Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects--a placebo controlled double blind investigation using 4 and 8 mg tolterodine extended release.
MedLine Citation:
PMID:  19637377     Owner:  NLM     Status:  MEDLINE    
AIMS: There is evidence that antimuscarinic drugs have depressant influence not only on bladder muscle activity, but also on bladder sensations. The aim of this study was to evaluate the effect of a single dose tolterodine extended release (ER) 4 and 8 mg on bladder sensations during filling cystometry. METHODS: After approval of the local ethics committee, 30 healthy female subjects (23.7 +/- 2.3 years) were included and randomly assigned to three groups: (A) placebo, (B) tolterodine ER 4 mg, and (C) tolterodine ER 8 mg in a double blind manner. Measurements were performed at baseline and 4 hr postmedication in each group, consisting of: (1) Filling cystometry with 25 ml/min at which subjects had to indicate first sensation of filling (FSF), first desire to void (FDV), and strong desire to void (SDV). (2) Uroflowmetry and ultrasound control for residual urine. RESULTS: In the placebo group, filling volumes at FDV and SDV decreased significantly posttreatment. This effect could not be observed for the tolterodine 8 mg group and only at SDV in the 4 mg group. No significant difference between groups was found regarding uroflowmetry parameters and postvoid residual volume. CONCLUSIONS: No increase of filling volumes in healthy subjects could be observed with tolterodine. However, the results suggest that tolterodine is able to alleviate irritation caused by repeated catheterization and cystometry. There was no significant influence of tolterodine ER 4 or 8 mg on voiding function.
Ulrich Mehnert; André Reitz; Sumaya Abo Youssef; Brigitte Schurch
Related Documents :
19523177 - Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of freque...
18662287 - Lamotrigine does not prolong qtc in a thorough qt/qtc study in healthy subjects.
25009187 - An estimate of the propagated uncertainty for a dosemeter algorithm used for personnel ...
19702487 - Efficacy and safety of dexmethylphenidate extended-release capsules administered once d...
19265287 - Collaborative work on evaluation of ovarian toxicity. 2) two- or four-week repeated dos...
7950347 - Clozapine-induced seizures and eeg changes.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neurourology and urodynamics     Volume:  29     ISSN:  1520-6777     ISO Abbreviation:  Neurourol. Urodyn.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-29     Completed Date:  2010-06-16     Revised Date:  2010-07-02    
Medline Journal Info:
Nlm Unique ID:  8303326     Medline TA:  Neurourol Urodyn     Country:  United States    
Other Details:
Languages:  eng     Pagination:  464-9     Citation Subset:  IM    
Copyright Information:
(c) 2009 Wiley-Liss, Inc.
Neurourology, Spinal Cord Injury Center, Balgrist University Hospital, Zürich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Benzhydryl Compounds / administration & dosage*
Cresols / administration & dosage*
Double-Blind Method
Muscarinic Antagonists / administration & dosage*
Phenylpropanolamine / administration & dosage*
Prospective Studies
Reference Values
Sensation / drug effects*
Urinary Bladder / drug effects*,  physiology*
Young Adult
Reg. No./Substance:
0/Benzhydryl Compounds; 0/Cresols; 0/Muscarinic Antagonists; 124937-51-5/tolterodine; 14838-15-4/Phenylpropanolamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of surface treatments on surface roughness, phase transformation, and biaxial flexural str...
Next Document:  The effect of loading on microTBS of four all-in-one adhesives on bonding to dentin.